Select Cognition Coverage and Published Editorials
Why The Best Biotech Leaders Take It Personally
Life Science Leader
By: Lisa Ricciardi
May 20, 2026
Transforming Neurodegenerative Disease Treatment
Fierce Biotech
With: Irena Luo
May 18, 2026
Blocking Toxic Oligomers: The Science and Strategy Behind Zervimesine
Psychiatric Times
May 11, 2026
Slowing Progression with Zervimesine in Dementia with Lewy Bodies
Psychiatric Times
May 8, 2026
Zervimesine Slows Symptom Progression at 6 Months in Dementia with Lewy Bodies
Healio Neurology
By: Isabella Hornick
April 30, 2026
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
MarketBeat
April 13, 2026
Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia with Lewy Bodies
Neurology Live
By: Noah Stansfield
March 24, 2026
AD/PD 2026 | Findings from the Phase 2a SHIMMER trial of zervimesine in mild-to-moderate DLB
Video Journal of Dementia
March 10, 2026
Cognition lengthens Zervimesine program in DLB
Bio Tuesdays
February 6, 2026
Type C Meeting With FDA Completed for Zervimesine in Dementia With Lewy Bodies
By: Jessica Walters
Psychiatric Times
January 27, 2026
Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug
Clinical Trial Vanguard
By: Jon Napitupulu
December 3, 2025
Cognition Therapeutics and FDA Align on Zervimesine Trial for Alzheimer’s
Clinical Trial Vanguard
By: Jon Napitupulu
August 14, 2025
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s
Clinical Trials Arena
By Abigail Beaney
July 30, 2025
New Data: Zervimesine for the Treatment of Dementia with Lewy Bodies and Alzheimer Disease
Psychiatric Times
By Leah Kuntz
July 29, 2025
Zervimesine in Alzheimer’s: Cognition Therapeutics and FDA Discuss Phase 2
Clinical Trial Vanguard
By Jon Napitupulu
July 11, 2025
Cognition soars 35% after positive FDA meeting on Alzheimer’s asset zervimesine
Seeking Alpha
By Jonathan Block
July 10, 2025
Connect with us on Social Media
